137 related articles for article (PubMed ID: 26497687)
41. Differential Emu enhancer activity and expression of BOB.1/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas.
Loddenkemper C; Anagnostopoulos I; Hummel M; Jöhrens-Leder K; Foss HD; Jundt F; Wirth T; Dörken B; Stein H
J Pathol; 2004 Jan; 202(1):60-9. PubMed ID: 14694522
[TBL] [Abstract][Full Text] [Related]
42. Large B-cell lymphoma with Hodgkin's features.
García JF; Mollejo M; Fraga M; Forteza J; Muniesa JA; Pérez-Guillermo M; Pérez-Seoane C; Rivera T; Ortega P; Piris MA
Histopathology; 2005 Jul; 47(1):101-10. PubMed ID: 15982329
[TBL] [Abstract][Full Text] [Related]
43. EBV-miR-BHRF1-2 targets PRDM1/Blimp1: potential role in EBV lymphomagenesis.
Ma J; Nie K; Redmond D; Liu Y; Elemento O; Knowles DM; Tam W
Leukemia; 2016 Mar; 30(3):594-604. PubMed ID: 26530011
[TBL] [Abstract][Full Text] [Related]
44. MiR-30a increases MDSC differentiation and immunosuppressive function by targeting SOCS3 in mice with B-cell lymphoma.
Xu Z; Ji J; Xu J; Li D; Shi G; Liu F; Ding L; Ren J; Dou H; Wang T; Hou Y
FEBS J; 2017 Aug; 284(15):2410-2424. PubMed ID: 28605567
[TBL] [Abstract][Full Text] [Related]
45. BRG1 regulation by miR-155 in human leukemia and lymphoma cell lines.
Cuadros M; Sánchez-Martín V; Herrera A; Baliñas C; Martín-Padrón J; Boyero L; Peinado P; Medina PP
Clin Transl Oncol; 2017 Aug; 19(8):1010-1017. PubMed ID: 28251496
[TBL] [Abstract][Full Text] [Related]
46. NGS-Based High-Throughput Screen to Identify MicroRNAs Regulating Growth of B-Cell Lymphoma.
Kluiver J; Niu F; Yuan Y; Kok K; van den Berg A; Dzikiewicz-Krawczyk A
Methods Mol Biol; 2019; 1956():269-282. PubMed ID: 30779039
[TBL] [Abstract][Full Text] [Related]
47. An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma.
Lollies A; Hartmann S; Schneider M; Bracht T; Weiß AL; Arnolds J; Klein-Hitpass L; Sitek B; Hansmann ML; Küppers R; Weniger MA
Leukemia; 2018 Jan; 32(1):92-101. PubMed ID: 28659618
[TBL] [Abstract][Full Text] [Related]
48. miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients.
Troppan K; Wenzl K; Pichler M; Pursche B; Schwarzenbacher D; Feichtinger J; Thallinger GG; Beham-Schmid C; Neumeister P; Deutsch A
Int J Mol Sci; 2015 Aug; 16(8):18077-95. PubMed ID: 26251897
[TBL] [Abstract][Full Text] [Related]
49. HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma.
Jia YJ; Liu ZB; Wang WG; Sun CB; Wei P; Yang YL; You MJ; Yu BH; Li XQ; Zhou XY
Leukemia; 2018 Mar; 32(3):703-711. PubMed ID: 29135973
[TBL] [Abstract][Full Text] [Related]
50. Expression of cyclin D2 and D3 in lymphoid lesions.
Teramoto N; Pokrovskaja K; Szekely L; Polack A; Yoshino T; Akagi T; Klein G
Int J Cancer; 1999 May; 81(4):543-50. PubMed ID: 10225442
[TBL] [Abstract][Full Text] [Related]
51. Plasma microRNA profiling: Exploring better biomarkers for lymphoma surveillance.
Khare D; Goldschmidt N; Bardugo A; Gur-Wahnon D; Ben-Dov IZ; Avni B
PLoS One; 2017; 12(11):e0187722. PubMed ID: 29131834
[TBL] [Abstract][Full Text] [Related]
52. LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas.
Zhang Y; Roccaro AM; Rombaoa C; Flores L; Obad S; Fernandes SM; Sacco A; Liu Y; Ngo H; Quang P; Azab AK; Azab F; Maiso P; Reagan M; Brown JR; Thai TH; Kauppinen S; Ghobrial IM
Blood; 2012 Aug; 120(8):1678-86. PubMed ID: 22797699
[TBL] [Abstract][Full Text] [Related]
53. MicroRNA-4728 serves as a suppressor and antagonist of oncogenic MAPK in Burkitt lymphoma.
Wang W; Lin P; Yao H; Jia X; Sun J; Feng L
Saudi J Biol Sci; 2018 Jul; 25(5):982-985. PubMed ID: 30108451
[TBL] [Abstract][Full Text] [Related]
54. Significance of the microRNA‑17‑92 gene cluster expressed in B‑cell non‑Hodgkin's lymphoma.
Yan S; Jia C; Quan L; Zhao L; Tian Y; Liu A
Mol Med Rep; 2019 Sep; 20(3):2459-2467. PubMed ID: 31322189
[TBL] [Abstract][Full Text] [Related]
55. Elderly Woman With No Autoimmune Disease With Aseptic Meningitis Caused by Celecoxib.
Takigawa M; Tanaka H; Kobayashi T; Katahara Y; Kinoshita M; Masuda M; Iwakiri R
Cureus; 2024 Mar; 16(3):e55348. PubMed ID: 38559550
[TBL] [Abstract][Full Text] [Related]
56. miR-24-3p Is Overexpressed in Hodgkin Lymphoma and Protects Hodgkin and Reed-Sternberg Cells from Apoptosis.
Yuan Y; Kluiver J; Koerts J; de Jong D; Rutgers B; Abdul Razak FR; Terpstra M; Plaat BE; Nolte IM; Diepstra A; Visser L; Kok K; van den Berg A
Am J Pathol; 2017 Jun; 187(6):1343-1355. PubMed ID: 28432871
[TBL] [Abstract][Full Text] [Related]
57. Plasma vesicle miRNAs for therapy response monitoring in Hodgkin lymphoma patients.
van Eijndhoven MA; Zijlstra JM; Groenewegen NJ; Drees EE; van Niele S; Baglio SR; Koppers-Lalic D; van der Voorn H; Libregts SF; Wauben MH; de Menezes RX; van Weering JR; Nieuwland R; Visser L; van den Berg A; de Jong D; Pegtel DM
JCI Insight; 2016 Nov; 1(19):e89631. PubMed ID: 27882350
[No Abstract] [Full Text] [Related]
58. miR-21 expression predicts prognosis in diffuse large B-cell lymphoma.
Li J; Fu R; Yang L; Tu W
Int J Clin Exp Pathol; 2015; 8(11):15019-24. PubMed ID: 26823838
[TBL] [Abstract][Full Text] [Related]
59. Pinpointing Functionally Relevant miRNAs in Classical Hodgkin Lymphoma Pathogenesis.
Pan Y; Cengiz R; Kluiver J; Diepstra A; Van den Berg A
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539461
[TBL] [Abstract][Full Text] [Related]
60. Unraveling the Role of the NLRP3 Inflammasome in Lymphoma: Implications in Pathogenesis and Therapeutic Strategies.
Stergiou IE; Tsironis C; Papadakos SP; Tsitsilonis OE; Dimopoulos MA; Theocharis S
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
